Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Orchid Pharma informed that the audio recording of its Analysts/Investors Earnings Call, held on May 26, 2026, is now available. Investors can access the recording via the provided link on the company's website.
May 26 2026 19:43:10
Orchid Pharma Ltd - 524372 - Appointment Of Internal Auditor Of The Company
Orchid Pharma's consolidated financial results for FY26 have received a qualified audit opinion from auditors. This qualification is due to the non-audited financial statements of certain US-based subsidiaries, a recurring issue.
May 25 2026 21:13:22
Orchid Pharma Ltd - 524372 - Statement Of Deviation Or Variation For The Quarter And Financial Year Ended On March 31, 2026
Orchid Pharma disclosed a deviation in the utilization of its Qualified Institutional Placement (QIP) funds for FY26. Approximately Rs. 61.98 crore, originally earmarked for a subsidiary's manufacturing facility, remains unutilized and is currently held in fixed deposits.
May 25 2026 19:58:58
Orchid Pharma Ltd - 524372 - Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31, 2026.
Orchid Pharma's board approved audited Q4 & FY26 standalone and consolidated financial results. Standalone net profit for Q4 FY26 was ₹30.60 cr, while consolidated net profit was ₹22.79 cr. The consolidated results had a modified audit opinion due to unaudited subsidiary financials.
May 25 2026 19:36:48
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Orchid Pharma will conduct an earnings call on May 26, 2026, at 04:30 PM (IST) to discuss the financial results for Q4 FY26 and the full fiscal year. Management will share insights on the company's performance.
May 19 2026 15:48:45
Orchid Pharma Limited
Orchid Pharma's Board of Directors is scheduled to meet on May 25, 2026. The primary agenda is to consider and approve the audited standalone and consolidated financial results for Q4 and the full financial year ended March 31, 2026.
May 19 2026 15:22:41
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) Of The Company For The Quarter-IV And Financial Year Ended On March 31, 2026
Orchid Pharma's Board of Directors is scheduled to meet on May 25, 2026. The key agenda for this meeting is to consider and approve the company's audited financial results for Q4 FY26 and the full financial year 2025-26.
May 19 2026 15:20:55
Orchid Pharma Limited
Orchid Pharma Ltd. filed a Q4 FY26 Monitoring Agency Report on QIP utilization. The report indicates a significant delay in the Jammu manufacturing facility's commercial operations, now expected by February 2027, due to land acquisition and other factors.
May 14 2026 16:52:23
Read More